The initial launch of biologics includes Axograft DBM Putty; Axograft Cancellous Crushed Allograft; Axograft Crunch Allograft; and Axograft Amniotic Membrane. The biological line is intended to complement X-spine’s line of spinal fixation products and will be used to promote spinal fusion, bone healing and wound treatment in spinal arthrodesis procedures.
More articles on devices:
What’s going on at Medtronic Spine? Innovations coming down the pipe
Medtronic’s new ACDF device designed to streamline procedures
Materialise buys OrthoView — 5 quick facts
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
